TITLE

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

AUTHOR(S)
Rockwood, K.; Mintzer, J.; Truyen, L.; Wessel, T.; Wilkinson, D.
PUB. DATE
November 2001
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Nov2001, p589
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66345808

 

Related Articles

  • Alzheimer's treatment benefits patients with severe disease'.  // GP: General Practitioner;12/5/2008, p3 

    The article reports on a randomised controlled trial of patients with severe Alzheimer's disease in Great Britain. The patients leaving in a nursing home received cholinesterase inhibitor galantamine for six months. The research found that galantamine has shown to improve cognitive function in...

  • New agents for Alzheimer's disease show benefit for at least 12 months.  // Geriatrics;Jun2000, Vol. 55 Issue 6, p63 

    Focuses on the benefits of galantamine drug in the treatment of Alzheimer's disease. Details on the trial conducted on the effectiveness of the drug; Side effects of the drug; Rationale for prolonging galantamine therapy.

  • Donepezil is more effective than galantamine for mild to moderate Alzheimer's disease. Jones, R. W.; Soininen, H.; Hager, K. // Evidence Based Mental Health;Aug2004, Vol. 7 Issue 3, p77 

    The article focuses on effects of donepezil compared with galantamine in people with mild to moderate Alzheimer's disease. A randomized controlled trial was conducted for this purpose. 120 people with Alzheimer's disease were willing to participate in this study. At 12 weeks, physicians and...

  • Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease [Corrigendum].  // Neuropsychiatric Disease & Treatment;2014, Vol. 10, p1997 

    A correction is presented to the article "Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease."

  • AD treatment may benefit patients with vascular dementia.  // Geriatrics;Jul2002, Vol. 57 Issue 7, p45 

    Presents an abstract of the study 'Efficacy of Galantamine in Probable Vascular Dementia and Alzheimer's Disease Combined With Cerebrovascular Disease: A Randomised Trial,' by T. Erkinjuntti, et al, published in the 2002 issue of the journal 'Lancet,'

  • Effect of galantamine on platelet functions in healthy elderly people. Isik, Ahmet Turan; Bozoglu, Ergun; Kaptan, Kursat; Celik, Turgay // Indian Journal of Medical Research;May2013, Vol. 137 Issue 5, p977 

    Background & objectives: Galantamine, a centrally-acting cholinesterase inhibitor, has been used in the treatment of mild-to-moderate dementia of Alzheimer disease. Increased mortality, mainly due to cardiovascular events, was observed in placebo-controlled trials of galantamine. Several studies...

  • Galantamine: A Pharmacoeconomic Review of its Use in Alzheimer's Disease. Lyseng-Williamson, K.A.; Plosker, G.L. // PharmacoEconomics;2002, Vol. 20 Issue 13, p919 

    Galantamine is one of several orally administered cholinesterase inhibitors that improve cognition in patients with mild to moderate Alzheimer's disease. Compared with placebo, galantamine 16 or 24 mg/day improved cognition and activities of daily living, delayed emergence of behavioural...

  • A Review of Clinical Pharmacokinetics and Pharmacodynamics of Galantamine, a Reversible Acetylcholinesterase Inhibitor for the Treatment of Alzheimer's Disease, in Healthy Subjects and Patients. Fenglei Huang; Yali Fu // Current Clinical Pharmacology;May2010, Vol. 5 Issue 2, p115 

    Galantamine is a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Following oral administration, galantamine is rapidly absorbed and reaches Cmax in approximately one hour for immediate release (IR) tablets and four hours for extended-release (ER) capsules....

  • Galantamine hydrobromide: An agent for Alzheimer's disease. Zarotsky, Victoria; Sramek, John J.; Cutler, Neal R. // American Journal of Health-System Pharmacy;3/1/2003, Vol. 60 Issue 5, p446 

    The pharmacology, dosage, adverse effects, efficacy, and economics of galantamine hydrobromide are discussed. Galantamine hydrobromide is a tertiary alkaloid that has been extracted from plant sources and is now synthesized for use in the treatment of mild to moderate Alz-heimer's disease (AD)....

  • Optimal Dosing of Galantamine in Patients with Mild or Moderate Alzheimer's Disease. Aronson, Stephen; Van Baelen, Bart; Kavanagh, Shane; Schwalen, Susanne // Drugs & Aging;2009, Vol. 26 Issue 3, p231 

    Background: Galantamine (hydrobromide), a reversible acetylcholinesterase inhibitor and allosteric nicotinic receptor modulator, slows cognitive and functional decline in mild to moderate dementia of the Alzheimer's type. Although several drugs are indicated for mild to moderate Alzheimer's...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics